Drugs / RPTR-168
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04762225 | May 2021 → Sep 2022 | cervical cancer, head and neck squamous cell carcinoma, melanoma | Repertoire Immune Medicines | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPTR-168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04762225 ↗ |
| Route | Intravenous | “RPTR-168 administered i.v. as a monotherapy” NCT04762225 ↗ |